SPARC has recently attracted substantial interest due to its roles in obesity, insulin resistance, and metabolic syndrome [77], and FGF21 is thought to have therapeutic potential for obesity, T2DM, and NAFLD [84]. The gene discussed is FGF21; the disease is type 2 diabetes mellitus.